Drug intelligence / Profile preview

SCY-575

Development stage: Preclinical
Lead developer: Scynexis
Modality: Small Molecules

Overview

SCY-575 is a cyclophilin inhibitor developed by SCYNEXIS. It was part of SCYNEXIS's cyclophilin inhibitor platform, which was designed to target viral diseases. In October 2014, SCYNEXIS granted Waterstone Pharmaceutical an option to develop and commercialize SCY-575, along with SCY-116, for treating viral diseases in humans. This indicates its intended use as an antiviral agent.

Targets

Cyp (Cyclophilin family)

Beyond the preview

Go deeper on SCY-575.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCY-575.

Explore the full profile